Evidence map›Paper›PMID 26305888›Full record

ArticleEndocrinology2015

Cognitive and Disease-Modifying Effects of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition in Male Tg2576 Mice, a Model of Alzheimer's Disease.

Karen Sooy, June Noble, Andrew McBride, Margaret Binnie, Joyce L W Yau, Jonathan R Seckl, Brian R Walker, Scott P Webster

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. 11β-HSD as a New Target in Pharmacotherapy of Metabolic Diseases.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Karen SooyUniversity/BHF Centre for Cardiovascular Science (K.S., J.N., A.M., M.B., J.L.W.Y., J.R.S., B.R.W., S.P.W.), Queen's Medical Research Institute, and Centre for Cognitive Aging and Cognitive Epidemiology (J.L.W.Y., J.R.S.), University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom.
June NobleUniversity/BHF Centre for Cardiovascular Science (K.S., J.N., A.M., M.B., J.L.W.Y., J.R.S., B.R.W., S.P.W.), Queen's Medical Research Institute, and Centre for Cognitive Aging and Cognitive Epidemiology (J.L.W.Y., J.R.S.), University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom.
Andrew McBrideUniversity/BHF Centre for Cardiovascular Science (K.S., J.N., A.M., M.B., J.L.W.Y., J.R.S., B.R.W., S.P.W.), Queen's Medical Research Institute, and Centre for Cognitive Aging and Cognitive Epidemiology (J.L.W.Y., J.R.S.), University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom.
Margaret BinnieUniversity/BHF Centre for Cardiovascular Science (K.S., J.N., A.M., M.B., J.L.W.Y., J.R.S., B.R.W., S.P.W.), Queen's Medical Research Institute, and Centre for Cognitive Aging and Cognitive Epidemiology (J.L.W.Y., J.R.S.), University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom.
Joyce L W YauUniversity/BHF Centre for Cardiovascular Science (K.S., J.N., A.M., M.B., J.L.W.Y., J.R.S., B.R.W., S.P.W.), Queen's Medical Research Institute, and Centre for Cognitive Aging and Cognitive Epidemiology (J.L.W.Y., J.R.S.), University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom.
Jonathan R SecklUniversity/BHF Centre for Cardiovascular Science (K.S., J.N., A.M., M.B., J.L.W.Y., J.R.S., B.R.W., S.P.W.), Queen's Medical Research Institute, and Centre for Cognitive Aging and Cognitive Epidemiology (J.L.W.Y., J.R.S.), University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom.
Brian R WalkerUniversity/BHF Centre for Cardiovascular Science (K.S., J.N., A.M., M.B., J.L.W.Y., J.R.S., B.R.W., S.P.W.), Queen's Medical Research Institute, and Centre for Cognitive Aging and Cognitive Epidemiology (J.L.W.Y., J.R.S.), University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom.
Scott P WebsterUniversity/BHF Centre for Cardiovascular Science (K.S., J.N., A.M., M.B., J.L.W.Y., J.R.S., B.R.W., S.P.W.), Queen's Medical Research Institute, and Centre for Cognitive Aging and Cognitive Epidemiology (J.L.W.Y., J.R.S.), University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom.
University of Edinburgh · GB

Funding

British Heart Foundation RG/11/4/28734Medical Research Council G0501596Medical Research Council MR/K026992/1Wellcome Trust
6 · The paper itself

Abstract

Chronic exposure to elevated levels of glucocorticoids has been linked to age-related cognitive decline and may play a role in Alzheimer's disease. In the brain, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) amplifies intracellular glucocorticoid levels. We show that short-term treatment of aged, cognitively impaired C57BL/6 mice with the potent and selective 11β-HSD1 inhibitor UE2316 improves memory, including after intracerebroventricular drug administration to the central nervous system alone. In the Tg2576 mouse model of Alzheimer's disease, UE2316 treatment of mice aged 14 months for 4 weeks also decreased the number of β-amyloid (Aβ) plaques in the cerebral cortex, associated with a selective increase in local insulin-degrading enzyme (involved in Aβ breakdown and known to be glucocorticoid regulated). Chronic treatment of young Tg2576 mice with UE2316 for up to 13 months prevented cognitive decline but did not prevent Aβ plaque formation. We conclude that reducing glucocorticoid regeneration in the brain improves cognition independently of reduced Aβ plaque pathology and that 11β-HSD1 inhibitors have potential as cognitive enhancers in age-associated memory impairment and Alzheimer's dementia.

Indexed as

11-beta-Hydroxysteroid Dehydrogenase Type 1Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsBehavior, AnimalCerebral CortexCognitionDisease Models, AnimalHumansInsulysinMaze LearningMemoryMiceMice, Inbred C57BLMice, Transgenic11-beta-Hydroxysteroid Dehydrogenase Type 1(4-(2-chlorophenyl-4-fluoro-1-piperidinyl)(5-(1H-pyrazol-4-yl)-3-thienyl)methanoneAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAPP protein, humanInsulysinPyrazolesThiophenes

Identifiers

PMID26305888
PMCPMC4655221
OpenAlexW1851348615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.